Barclays PLC Ascendis Pharma A/S Put Options Transaction History

Barclays PLC

5 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 15, 2024	BUY	$123.45 - $159.4 $6.17 Million - $7.97 Million	50,000 Added 222.22%	72,500 $11 Million
Q4 2023 Feb 15, 2024	BUY	$86.1 - $127.36 $1.94 Million - $2.87 Million	22,500 New	22,500 $2.83 Million
Q3 2021 Nov 09, 2021	SELL	$112.67 - $176.92 $3.23 Million - $5.08 Million	-28,700 Reduced 42.84%	38,300 $6.11 Million
Q1 2019 May 15, 2019	BUY	$62.15 - $129.99 $1.8 Million - $3.76 Million	28,900 Added 75.85%	67,000 $7.89 Million
Q4 2018 Feb 14, 2019	BUY	$55.16 - $69.67 $2.1 Million - $2.65 Million	38,100 New	38,100 $2.39 Million

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.